

## **Product** Data Sheet

## AChE/BuChE-IN-2

 Cat. No.:
 HY-146142

 CAS No.:
 1946008-31-6

 Molecular Formula:
 C<sub>20</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub>

 Molecular Weight:
 318.37

Target:AChE; Amyloid-βPathway:Neuronal Signaling

Storage: Please store the product under the recommended conditions in the Certificate of

Analysis.

## **BIOLOGICAL ACTIVITY**

Description	AChE/BuChE-IN-2 (Compound 5f) is an orally active AChE and BuChE inhibitor with IC $_{50}$ values of 0.72 $\mu$ M and 0.16 $\mu$ M, respectively. AChE/BuChE-IN-2 shows a non-competitive inhibition with AChE and shows potent self-induced $\beta$ -amyloid (A $\beta$ ) aggregation inhibition with an IC $_{50}$ of 62.52 $\mu$ M. AChE/BuChE-IN-2 can cross the BBB <sup>[1]</sup> .
IC <sub>50</sub> & Target	IC $_{50}$ : 0.16 μM (BuChE), 0.72 μM (AChE), 62.52 μM (A $\beta$ aggregation) $^{[1]}$
In Vivo	AChE/BuChE-IN-2 (Compound 5f) (20 $\mu$ mol/kg) significantly ameliorates the cognitive performances of scopolamine-treated ICR mice <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

## **REFERENCES**

[1]. Luo W, et al. Synthesis, in vitro and in vivo biological evaluation of novel graveolinine derivatives as potential anti-Alzheimer agents. Bioorg Med Chem. 2020 Jan 1;28(1):115190.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

 $\hbox{E-mail: } tech@MedChemExpress.com$ 

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA